Premedication with non-selective and M1-selective muscarinic antagonists before ECT

Area of Science:

• Anesthesiology
• Pharmacology
• Neuroscience

Background:

• Premedication with atropine before electroconvulsive therapy (ECT) is standard practice.
• Atropine is used to prevent bradyarrhythmias and reduce respiratory secretions post-ECT.
• The precise mechanism of atropine's protective effects, central versus peripheral, remains unclear.

Purpose of the Study:

• To compare the efficacy of atropine (non-selective muscarinic antagonist) and biperiden (M1-selective muscarinic antagonist) in managing post-ECT autonomic effects.
• To elucidate whether atropine's effects on cardiac and respiratory parameters involve central or peripheral muscarinic receptor antagonism.
• To investigate the specific muscarinic receptor subtypes (M1 vs. M2) involved in atropine's actions.

Main Methods:

• A comparative study involving patients undergoing ECT.
• Patients received premedication with either atropine or biperiden.
• Cardiac parameters (heart rate, etc.) and respiratory tract secretions were measured and compared post-ECT.

Main Results:

• Atropine significantly reduced sialorrhea (excessive salivation) post-ECT, indicating antagonism via peripheral M2 receptors.
• Biperiden, an M1 antagonist, did not prevent sialorrhea, suggesting M1 receptors are not primarily involved in this effect.
• No bradyarrhythmias were observed in either group, and no significant differences in cardiac parameters were found between atropine and biperiden premedications.

Conclusions:

• Atropine's anti-sialorrhea effect post-ECT is mediated through peripheral M2 receptor antagonism.
• The study could not definitively conclude whether atropine's potential cardiac protective effects involve central or peripheral mechanisms.
• Further research is needed to clarify the role of central versus peripheral muscarinic receptors in atropine's cardiac actions following ECT.